- Home
- JSPR vs CMPS Comparison
JSPR vs CMPS Comparison
Compare JSPR & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- CMPS
- Stock Information
- Founded
- JSPR 2018
- CMPS 2020
- Country
- JSPR United States
- CMPS United Kingdom
- Employees
- JSPR N/A
- CMPS N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- CMPS Health Care
- Exchange
- JSPR Nasdaq
- CMPS Nasdaq
- Market Cap
- JSPR 85.8M
- CMPS 364.9M
- IPO Year
- JSPR N/A
- CMPS 2020
- Fundamental
- Price
- JSPR $6.82
- CMPS $3.38
- Analyst Decision
- JSPR Strong Buy
- CMPS Strong Buy
- Analyst Count
- JSPR 10
- CMPS 7
- Target Price
- JSPR $62.22
- CMPS $17.83
- AVG Volume (30 Days)
- JSPR 369.8K
- CMPS 5.0M
- Earning Date
- JSPR 08-12-2025
- CMPS 07-31-2025
- Dividend Yield
- JSPR N/A
- CMPS N/A
- EPS Growth
- JSPR N/A
- CMPS N/A
- EPS
- JSPR N/A
- CMPS N/A
- Revenue
- JSPR N/A
- CMPS N/A
- Revenue This Year
- JSPR N/A
- CMPS N/A
- Revenue Next Year
- JSPR N/A
- CMPS N/A
- P/E Ratio
- JSPR N/A
- CMPS N/A
- Revenue Growth
- JSPR N/A
- CMPS N/A
- 52 Week Low
- JSPR $3.13
- CMPS $2.25
- 52 Week High
- JSPR $26.05
- CMPS $8.54
- Technical
- Relative Strength Index (RSI)
- JSPR 72.52
- CMPS 45.23
- Support Level
- JSPR $5.35
- CMPS $2.25
- Resistance Level
- JSPR $5.72
- CMPS $2.82
- Average True Range (ATR)
- JSPR 0.51
- CMPS 0.38
- MACD
- JSPR 0.07
- CMPS -0.11
- Stochastic Oscillator
- JSPR 97.40
- CMPS 38.97
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.